Pharma research products compete for €1bn funding pots

Published: 13-May-2011
Finance

Two medicine-related research projects on the short list


The European Commission has selected two medicine-related research projects in a shortlist of six that will compete for two EU funding agreements, each worth €1bn.

One of these competitors is called ‘IT Future of Medicine’ and involves the study of digital technology to deliver individualised medicine, based on molecular, physiological and anatomical data collected from individual patients.

The other is named ‘the Human Brain project’ that will assess the way human brains work to inspire medicine, neuroscience and computing systems. Both have been awarded €1.5m to develop a research proposal over the next 12 months to present to the Commission. It will then decide whether either or both of them will be awarded 10 years of up to €100m funding grants.

See more

You may also like

Drug Delivery

Adult vaccination programmes deliver significant socio-economic benefits, study finds

Read more
The study shows that adult immunisation programmes return 19x their initial investment, which could ease the pressure on health systems

Trending Articles

  1. Small molecules: big market opportunities The rapid rise of biologic drugs in recent years has been accompanied by a market narrative that suggests that innovation and new treatments will be fuelled by breakthroughs in this area, leading to a decline in the small molecule pipeline. This is far from true, notes Kevin Cook, Chief Executive Officer at Sterling Pharma Solutions; both are increasing and small molecule drugs continue to be a mainstay of many drug development portfolios
  2. Policy vacuum risks UK becoming a medicines supply backwater The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
  3. Lonza appoints President of Capsules and Health Ingredients Christian Seufert joins from BASF, where he has worked for the last 20 years. Most recently, he held the role of Senior VP for the Global Business Unit Pharma Solutions
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    The pros and cons of distribution agreements For life sciences companies seeking to break into overseas markets, distribution agreements are central to success
  5. AstraZeneca to stop production of Pulmicort pMDI Agreements with SkyePharma expected to be terminated

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Drug Delivery

Adult vaccination programmes deliver significant socio-economic benefits, study finds

The study shows that adult immunisation programmes return 19x their initial investment, which could ease the pressure on health systems
Regulatory

Policy vacuum risks UK becoming a medicines supply backwater

The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
Hi Tech Manufacturing

Johnson Matthey agrees to sell Medical Device Components business

The business has been sold to Montagu Private Equity for USD $700m
Finance

Fusion Pharmaceuticals to be acquired by AstraZeneca for up to $2.4bn

Fusion developed a Targeted Alpha Therapies platform together with linker technology to selectively deliver cancer therapies
Research & Development

AstraZeneca to acquire Amolyt Pharma for up to $1.05 billion

The acquisition will facilitate the development of novel therapeutics for rare endocrine and related diseases
Manufacturing

Almac Sciences awarded Life Sciences Innovative Manufacturing Fund grant

Grant awarded to support the expansion of Almac’s small molecule API manufacturing plant
Manufacturing

Sarcura secures a €1.7M grant to accelerate cell therapy manufacturing platform

The funding will accelerate the development a miniaturised and autonomous cell therapy manufacturing platform
Subscribe now